Healthcare
Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025
Following a 38-to-1 stock split and explosive rally, the biotech firm's volatile trading persists despite a multi-year loss streak Regencell...
EXCLUSIVE: MIRA Pharmaceuticals’ Disruptive Path In Neurology And Metabolic Disorders
CEO Erez Aminov on Breakthrough Drug Candidates, Strategic Acquisitions, and the Vision Behind MIRA’s Innovation-Driven Pipeline MIRA Pharmaceuticals (NASDAQ: MIRA),...
MIRA Pharmaceuticals Secures Key Publication for Ketamir-2, a Next-Gen Ketamine Analog
Peer-reviewed journal spotlights differentiated pharmacology and therapeutic promise for neuropathic pain MIRA Pharmaceuticals (MIRA), a clinical-stage biotech firm focused on...
Telomir Pharmaceuticals Reports Breakthrough Anti-Aging Results in Preclinical Werner Syndrome Model
Lead candidate Telomir-1 reverses aging markers, restores muscle mass, and boosts survival in genetic progeria model Telomir Pharmaceuticals (TELO), a...
Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss
Telomir-1 reverses retinal degeneration and restores vision in advanced AMD zebrafish model Telomir Pharmaceuticals (TELO) announced a major preclinical breakthrough...
Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program
Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1 Telomir Pharmaceuticals (TELO), a biotech innovator...
Institutional Interest In Telomir Pharmaceuticals
Telomir Pharmaceuticals (TELO) has caught the attention of institutional investors, with JPMorgan Chase & Co. (JPM) significantly increasing its position...
KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets
$710 Million Raised as David Bailey Leads Ambitious Plan to Transform Bitcoin Adoption Through Public Equity In a landmark move...
Mira Pharmaceuticals Approves Acquisition of SKNY, Creating $60M+ Biotech Platform
Board approves merger following independent valuation; SKNY to contribute $5M in cash or assets at closing Mira Pharmaceuticals (MIRA), a...
Hims & Hers Health Doubles Revenue in Q1 2025, Raises Full-Year Outlook
Surging subscriber growth and profitability prompt ambitious long-term targets for 2030 Hims & Hers Health, Inc. (HIMS), a leading digital...
